Kevin M. Hart

Kevin M. Hart

Auto-generated profile, based on publicly available information

Kevin M. Hart

Immunopathogenesis Section, Laboratory of Parasitic Diseases National Institute of Allergy and Infectious Diseases, National Institutes of Health Bethesda MD USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
KHKevin M. Hart
Kevin M. Hart
TFThomas Fabre
Thomas Fabre
JSJoshua C. Sciurba
Joshua C. Sciurba
RGRichard L. Gieseck
Richard L. Gieseck
LBLee A. Borthwick
Lee A. Borthwick
TWThomas A. Wynn
Thomas A. Wynn
Development of NASH fibrosis is accompanied by accumulation of hepatic eosinophils and driven by TGF-β and profibrotic type 2 inflammation.

7 December 2018 in The Journal of Pathology
Verified
Journal Article
Open access
PDF file
JSJoshua C. Sciurba
Joshua C. Sciurba
RGRichard L Gieseck
Richard L Gieseck
NJNikhil Jiwrajka
Nikhil Jiwrajka
SWSandra D. White
Sandra D. White
EKErik P. Karmele
Erik P. Karmele
KHKevin M. Hart
Kevin M. Hart
Fibroproliferative diseases affect a significant proportion of the world's population. Despite this, core mechanisms driving organ fibrosis of diverse etiologies remain ill defined. Recent studies suggest that integrin‐alpha V serves as a master driver of fibrosis in multiple organs. Although diverse mechanisms contribute to the progression of fibrosis, TGF‐β and IL‐13 have emerged as central mediators of fibrosis during type 1/type 17, and type 2 polarized inflammatory responses, respectively. To investigate if integrin‐alpha V interactions or signaling is critical to the development of type 2 fibrosis, we analyzed fibroblast‐specific integrin‐alpha V knockout mice in three type 2‐driven inflammatory disease models. While we confirmed a role for integrin‐alpha V in type 17‐associated fibrosis, integrin‐alpha V was not critical to the development of type 2‐driven fibrosis. Additionally, our studies support a novel mechanism through which fibroblasts, via integrin‐alpha V expression, are capable of regulating immune polarization. We show that when integrin‐alpha V is deleted on fibroblasts, initiation of type 17 inflammation is inhibited leading to a deregulation of type 2 inflammation. This mechanism is most evident in a model of severe asthma, which is characterized by a mixed type 2/type 17 inflammatory response. Together, these findings suggest dual targeting of integrin‐alpha V and type 2 pathways may be needed to ameliorate fibrosis and prevent rebound of opposing pro‐fibrotic and inflammatory mechanisms. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.